中国美容医学2012，Vol.21Issue(14)：252-253,2.
新型国产替罗非班在非介入治疗的急性非ST段抬高型心肌梗死患者的疗效与安全性观察
Model of domestic tirofiban in the interventional treatment of acute non ST segment elevation myocardial infarction observation of efficacy and safety
杨遇春 1吴明祥 1张治平 1刘波 1刘心甜 1刘成伟 1鄢华1
作者信息
- 1. 武汉亚洲心脏病医院重症监护病房 湖北武汉430022
- 折叠
摘要
Abstract
Objective To evaluate the safety and efficacy of a new generation of domestic tirofiban (Qu zhiquan),a specific inhibitorof the plateletglycoprotein II b/Ⅲ areceptorjn the treatment of acute non ST segment elevation myocardial infarction (NSTEMI). Method A total of 102 patients were randomly assigned to receive standard antithrombotic therapy (low molecular weight heparin and aspirin plus clopidogrel), or standard antithrombotic therapy plus Qu Zhiquan. The composite primary end point consisted of death, myocardial infarction, refractoryischemi,or bleeding complication. Results The frequency of the MACE end point at 30 days was lower among the patients who received the Qu zhiquan plus standard antiplatelet than among those who received standard antiplatelet (13.9 percent vs 29.3 percent:P <0.01).The rates of the angina pectoris in the Qu zhiquan plus standard antiplatelet group were also lower than those in the standard antiplatelet group at 7 days. Bleeding complication occurred in 7.0 percent of the patients receiving standard antiplatelet alone and 12.7 percent of the patients receivmg combination Therapy (P >0.05). Two groups of there were no major bleeding events. Conclusions The new generation of domestic tirofiban-Qu zhiquan was associated with a lower incidence of ischemi cevents in patients with NSTEMI than in patients who received only standard antiplatelet:might be of special value in patients with NSTEMI.关键词
替罗非班/曲之全/急性非ST段抬高型心肌梗死/安全性Key words
tirofiban/Qu zhiquan/ non ST segment elevation myocardial infarction/ safety分类
医药卫生引用本文复制引用
杨遇春,吴明祥,张治平,刘波,刘心甜,刘成伟,鄢华..新型国产替罗非班在非介入治疗的急性非ST段抬高型心肌梗死患者的疗效与安全性观察[J].中国美容医学,2012,21(14):252-253,2.
